## AMENDMENTS TO THE CLAIMS

- 1. (previously presented) A solid pharmaceutical composition suitable for the oral delivery of a pharmacologically active agent comprising
  - a. a therapeutically-effective amount of a pharmacologically active agent;
  - b. a crospovidone or povidone; and
  - c. a delivery agent for said pharmacologically active agent.
- (previously presented) A composition according to claim 1 wherein the active agent is a peptide.
- 3. (previously presented) A composition according to claim 2 wherein the peptide is a calcitonin.
- 4. (previously presented) A composition according to claim 3 wherein the calcitonin is salmon calcitonin.
- 5. (previously presented) A composition according to claim 1 comprising crospovidone.
- 6. (previously presented) A composition according to claim 1 wherein the delivery agent is 5-CNAC.
- 7. (previously presented) A composition according to claim 1 wherein the delivery agent is the disodium salt of 5-CNAC.
- 8. (previously presented) A composition according to claim 1 which additionally includes a diluent.
- 9. (previously presented) A composition according to claim 8 wherein the diluent is microcrystalline cellulose.
- 10. (previously presented) A composition according to claim 1 which additionally includes a lubricant.
- 11. (previously presented) A composition according to claim 10 wherein the lubricant is magnesium stearate.
- 12. (withdrawn) A method for enhancing the oral bioavailability of a pharmacologically active agent, said method comprising administering to a patient in need of a pharmacologically active agent, an effective amount of a pharmaceutical composition according to claim1.

- 13. (withdrawn) A method of treatment of bone related diseases and calcium disorders comprising administering to a patient in need of such treatment a therapeutically effective amount of a composition according to claim 1, wherein said pharmacologically active agent is calcitonin.
- 14. (withdrawn) A method according to claim 13 wherein said calcitonin is salmon calcitonin.
- 15. (previously presented) A solid pharmaceutical composition suitable for the oral delivery of a pharmacologically active agent comprising:
  - a. salmon calcitonin;
  - b. crospovidone;
  - c. 5-CNAC;
  - d. optionally, microcrystalline cellulose; and
  - e. optionally, magnesium stearate.
- 16. (currently amended) A solid pharmaceutical composition according to claim 15 wherein
  - a. the salmon calcitonin comprises from is present in an amount of from 0.05-70% by weight relative to the total weight of the overall pharmaceutical composition;
  - b. the crospovidone or povidone comprises from is present in an amount of from 0.5-50% by weight relative to the total weight of the overall pharmaceutical composition; and
  - c. the 5-CNAC is present in an amount of <u>from</u> 2.5-99.4% by weight relative to the total weight of the overall pharmaceutical composition.
- 17. (new) A solid pharmaceutical composition according to claim 15 wherein the crospovidone or povidone is present in an amount of from 2-25% by weight relative to the total weight of the overall pharmaceutical composition.
- 18. (new) A solid pharmaceutical composition according to claim 1 wherein
  - a. the pharmacologically active agent is present in an amount of from 0.05-70% by weight relative to the total weight of the overall pharmaceutical composition;
  - b. the crospovidone or povidone is present in an amount of from 0.5-50% by weight relative to the total weight of the overall pharmaceutical composition; and
  - c. the delivery agent for said pharmacologically active agent is present in an amount of 2.5-99.4% by weight relative to the total weight of the overall pharmaceutical composition.
- 19. (new) A solid pharmaceutical composition according to claim 18 wherein

the crospovidone or povidone is present in an amount of from 2-25% by weight relative to the total weight of the overall pharmaceutical composition.